CDBIO(SH:688739) Zheng Quan Shi Bao·2025-10-21 17:28Core Insights - Company signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases and vector-borne disease prevention [2][3] - The collaboration aims to leverage both parties' resources and expertise to enhance research and development in vaccine and biopharmaceuticals [3] Group 1: Strategic Collaboration - The agreement emphasizes joint applications for national and provincial research projects to secure government support and resources [2] - Both parties will establish a long-term partnership to share resources and amplify their efforts in infectious disease prevention [2][3] Group 2: Research and Development Focus - The collaboration will enhance the company's vaccine development platform by integrating top-tier resources from the Institute of Microbiology [3] - The partnership aims to accelerate the R&D process for vaccines and biopharmaceuticals targeting emerging infectious diseases [3] Group 3: Intellectual Property and Confidentiality - Each party retains ownership of their respective intellectual property, with jointly developed results being co-owned as per specific agreements [3] - Both parties will maintain confidentiality regarding project details and proprietary technologies throughout the collaboration [3] Group 4: Long-term Strategy - The strategic cooperation aligns with the company's long-term strategy to focus on vaccines while expanding into the biopharmaceutical sector [3] - The agreement is considered an intention for collaboration and is not expected to have a direct impact on the company's performance until specific projects are advanced [3]